NasdaqGM:MNKDBiotechs
MannKind (MNKD) Valuation Check As Afrezza Pediatric Milestones Open Needle Free Insulin Opportunity
MannKind (MNKD) is back in focus after enrolling the first pediatric patient in its INHALE-1ST Afrezza study and advancing an FDA review that could make Afrezza the first needle-free insulin option for children.
See our latest analysis for MannKind.
The latest Afrezza pediatric milestones come as MannKind’s 30 day share price return of 8.64% and 90 day share price return of 13.20% point to building momentum, while its 1 year total shareholder return of 4.43% and 5 year total shareholder...